ReviewBioscience reports2025
Evolving stratification and biomarker discovery in cancer research with technological advancement of proteomics: 35 years and counting.
Review in Bioscience reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Proteome, the molecular product of regulatory diktat of the cellular machinery, predicts the behaviour and progression of cancers. Designing effective molecular therapies based on proteins with comprehensive patient stratification remains the mainstay of every translational research. Research on the proteome involves a) identification of biomarkers that, with utmost sensitivity and specificity, reveal significant insights into the disease state and b) understanding the mechanistic underpinnings and rewiring of cellular signaling pathways that drive a particular cancerous pathology. In this review, we give a comprehensive description of the evolution of mass spectrometer-based methods, including labeling strategies available to study the proteome and post-translational modifications in response to various perturbations. We summarize their utility in understanding complex processes of cancers, advance research on cancer therapy by decoding novel biomarkers, identify therapy resistance drivers, and enhance spatial attributes of tumor microenvironment by single-cell proteomics. Finally, some of the challenges in the currently used methods have been discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.